NCT06553885

Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC

A Phase II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic Colorectal Cancer or Hepatocellular Carcinoma

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: H. Lee Moffitt Cancer Center and Research Institute · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is a multi-indication, open-label, single-treatment arm, parallel-cohort phase II study of enfortumab vedotin in adult participants with advanced or metastatic colorectal cancer (CRC) or hepatocellular carcinoma (HCC) who have been previously treated with one or more lines of systemic therapy.

Conditions

• Metastatic Colorectal Cancer
• Hepatocellular Carcinoma

Interventions

Type	Name	Description
DRUG	Enfortumab Vedotin	Enfortumab vedotin is a type of prescription medicine known as an antibody-drug conjugate.

Timeline

• Start date: 2025-04-01
• Primary completion: 2029-09-01
• Completion: 2029-09-01
• First posted: 2024-08-14
• Last updated: 2026-04-01

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study